Xeno Transplants Corporation
Xeno Transplants Corporation
Your view on XENO
Overview
What the company does, where it operates, and who runs it.
About Xeno Transplants Corporation
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Elliot Lebowitz
- Headquarters
- 143 Gardner Road, Brookline, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Elliot Lebowitz
- Headquarters
- 143 Gardner Road, Brookline, MA, US
Xeno Transplants Corporation operates as a bio-technology research and development company. The company, through a license agreement with Massachusetts General Hospital, intends to develop, manufacture, distribute, and use products and processes for public use with regard to xenotransplantation.
The Xenotransplantation is intended to address the problems arising from the limited supply of available human cells, tissues, and organs for transplantation by developing technologies to permit the transplantation of cells, tissues, and organs from other species into humans, such as swine.
Xeno Transplants Corporation was incorporated in 2004 and is based in Brookline, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Xeno Transplants Corporation, and the rating behind it. XENO last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Xeno Transplants Corporation. Starting points for Xeno Transplants Corporation: beta -28.50 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Xeno Transplants Corporation. Xeno Transplants Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Xeno Transplants Corporation. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Xeno Transplants Corporation. Xeno Transplants Corporation has reported as a listed company since 2006. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Xeno Transplants Corporation valued side by side against its closest peers. Xeno Transplants Corporation is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Xeno Transplants Corporation, and how their positions are changing. At a $4,036 market value, institutional positions materially move Xeno Transplants Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Xeno Transplants Corporation executives and directors. Shares of Xeno Transplants Corporation have traded between $0.0001 and $0.0001 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Xeno Transplants Corporation. Xeno Transplants Corporation is a $4,036 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Xeno Transplants Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Xeno Transplants Corporation. Coverage tracks Xeno Transplants Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.